News

FDA’s new approach raises questions about fall COVID vaccine availability
Health experts say there are legitimate questions about how much everyone still benefits from yearly COVID vaccination or ...
STAT19m
Investors unfazed by FDA’s Covid vaccine framework
The FDA announced yesterday that it will limit access to Covid-19 vaccines to people 65 years of age and older and others who ...
pharmaphorum24m
US imposes limits on COVID-19 boosters and new jabs
The policy has been outlined in an editorial in the New England Journal of Medicine (NEJM) by FDA Commissioner Marty Makary ...
Moderna pulls application for COVID-flu combination shot
Moderna said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine ...
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...
BioSpace3h
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director ...
McKnight's Long-Term Care News11h
Older adults gain new COVID vaccine option as FDA approves protein-based shot
The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...